Florida Cancer Specialists & Research Institute Champions the Impact of Integrated Oncology At NCODA International Summit

FORT MYERS, Fla., Oct. 15, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) physician leaders and pharmacy experts this week are participating in the 2025 NCODA International Fall Summit. Alongside oncology professionals from around the globe, they will share the latest insights on how medically integrated practices are advancing patient-centered care and optimizing outcomes for those undergoing cancer treatment.

Lucio N. Gordan, MD, FCS president & managing physician, who serves on the NCODA board of directors, executive council, and the event's steering committee, said, "Sessions at the NCODA Fall Summit are highly informative and thought provoking. The practical insights and tools shared are directly applied to enhance patient care provided across our statewide practice."

FCS is the summit's host sponsor. Dr. Gordan will give opening remarks, kicking off the first full day of the event, where FCS Associate Director of Pharmacy Clinical Services Chris Elder, PharmD, BCOP, a member of the summit planning committee and 2024 recipient of NCODA's Living the Mission Award, will announce the 2025 winner.

Additionally, Elder will be a featured presenter for the session, "Redefining the Treatment of Squamous Cell Carcinoma of the Anal Canal (SCAC) ZYNYZ^® (retifanlimab-dlwr): The First and Only FDA-Approved PD-1 Inhibitor for Adults with Inoperable Locally Recurrent or Metastatic SCAC."

Paul Chadwick, FCS chief value & procurement officer said, "We are proud to share our best practices while learning from our colleagues to ensure optimal outcomes for our patients."

FCS physicians, pharmacists and leaders maintain active participation in leadership roles with NCODA:

• Lucio N. Gordan, MD, FCS president & managing physician – Board of Directors and Executive Council
• Paul Chadwick, FCS chief value & procurement officer – Executive Council
• Austin Cox, PharmD, FCS senior director of trade relations – Executive Council

In an article published ahead of the annual conference in NCODA's Oncolytics Today Fall 2025 issue, several FCS leaders, Lucio N. Gordan, MD, Director, Real-World Evidence Amanda Warner and Precision Oncology Informatics Lead Ivenise Carrero Gonzalez, PhD, are co-authors of A Review of Liquid, Tissue Based and Combined Next-Generation Sequencing with a Focus on NSCLC, Colorectal, Breast and Prostate Cancers, highlighting the necessity of liquid and tissue next-generation sequencing, particularly when treating lung, colorectal, breast and prostate cancers.

Rx To Go, FCS' in-house medically integrated pharmacy, delivers personalized support to patients receiving oral chemotherapy. It is accredited by URAC for Specialty Pharmacy, Accreditation Commission for Health Care (ACHC) with Oncology Distinction, and dually accredited by the National Association of Boards of Pharmacy^® (NABP^®) for specialty pharmacy and digital pharmacy practice.

NCODA is a globally recognized not-for-profit organization dedicated to building a patient-centered, medically integrated community of health care providers whose focus is to innovate the continuity of cancer care so that every patient receives the maximum benefit from their cancer treatment.

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program.

FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. In fact, before receiving FDA approval, the majority of new cancer drugs in the U.S. were first made available to patients through participation in clinical trials at FCS.

Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that make the best use of cutting-edge precision oncology advancements to enhance patient outcomes.

SOURCE Florida Cancer Specialists & Research Institute